Characteristics | N=57 |
Age (years), median (Q1–Q3) | 56.5 (45.8–63.8) |
Sex, n (%) | |
Male | 30 (52.6) |
Female | 27 (47.4) |
ECOG PS, n (%) | |
0 | 20 (35.1) |
1 | 37 (64.9) |
Primary tumor location, n (%) | |
Right-sided | 31 (54.4) |
Left-sided | 25 (43.9) |
Right and left location | 1 (1.8) |
Mutation status, n (%) | |
RAS/RAF wild type | 19 (33.3) |
RAS mutation | 28 (49.1) |
BRAF mutation | 10 (17.5) |
Origin of MMR deficiency, n (%) | |
Lynch-related | 32 (56.1) |
Known germline mutation | 19 (59.4) |
Sporadic | 16 (28.1) |
Unknown | 9 (15.8) |
Number of metastatic sites, n (%) | |
1 | 16 (28.1) |
2 | 25 (43.9) |
>2 | 16 (28.1) |
Number of prior lines, n (%) | |
1 | 5 (8.8) |
2 | 24 (42.1) |
>2 | 27 (47.4) |
Missing | 1 (1.8) |
Prior treatments, n (%) | |
5-FU/capecitabine | 57 (100.0) |
Oxaliplatin | 57 (100.0) |
Irinotecan | 55 (96.5) |
Trifluridine/tipiracil | 4 (7.0) |
Regorafenib | 5 (8.8) |
Bevacizumab/aflibercept | 33 (57.9) |
Cetuximab/panitumumab | 26 (45.6) |
ECOG PS, The Eastern Cooperative Oncology Group Performance Status; 5-FU, 5-fluorouracil; MMR, DNA mismatch repair.